Duchenne Muscular Dystrophy (DMD) Treatment Market Global Analysis 2019-2026: Key Findings, Recent Trends, Regional Study, Top Key Players Profiles and Future Prospects

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy that usually begins around the age of four in boys and worsens quickly. In layman’s terms, it is a genetic disorder, which is characterized by progressive muscle degeneration and weakness. DMD is caused due to alteration in gene sequence coding for dystrophin protein, present in the muscle. Although it is a rare disorder, it typically affects males. Its symptoms includes intellectual disability, muscle weakness and, difficulty in walking, and breathing. Moreover, a patient may suffer congestive heart failure, mental impairment, pneumonia or respiratory failure. DMD is not curable though there are treatment options available to control or reduce the signs and symptoms. Clinicians prescribe steroid drugs to control the symptoms of DMD. Moreover, stem cell therapy and gene therapy could be used for treatment of this disease in future.

A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/898

Market Dynamics- Drivers

Growing investments in the research and development, to find out effective treatment for DMD is driving the growth of global Duchenne muscular dystrophy (DMD) treatment market

Growing incidence of DMD cases is expected to drive growth of the global Duchenne muscular dystrophy (DMD) treatment market during the forecast period. According to the Centers for Disease Control and prevention (CDC) 2007, 349 out of 2.37 million males in the U.S. were reported to be suffering from DMD. According to the same source, in 2019, 349 new cases of DMD were reported. Several organizations are focused on spreading awareness and investing in research and development to find the effective treatment for this disease, which is expected to drive growth of the global Duchenne muscular dystrophy treatment market. For instance, Muscular Dystrophy Association (MDA), U.S. invests US$ 75,000 in research and development to develop treatment for Duchenne muscular dystrophy. Moreover, the association funds over 150 care centers, health care facility centers, and hospitals across the U.S. and in other countries. Furthermore, continuous research on stem cell therapy, gene therapy, and exon skipping drugs for the treatment of DMD is expected to propel the growth of the global Duchenne muscular dystrophy (DMD) treatment market in the near future.

Quick Buy – Duchenne Muscular Dystrophy (DMD) Treatment Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/898

Market Dynamics- Restraints

Low seeking rate due to prognosis and late diagnosis of this disease worldwide is expected to restrain growth of the global Duchenne muscular dystrophy (DMD) treatment market over the forecast period.

Rising hospitalization for DMD is the factor helping the hospital segment to hold the maximum share in global Duchenne muscular dystrophy (DMD) treatment market

The global Duchenne muscular dystrophy (DMD) treatment market is segmented by therapy, by product type, by end users, and by regions.

On the basis of type of therapy, the global Duchenne muscular dystrophy (DMD) treatment   market is segmented into

• Mutation suppression
• Exon skipping approach
• others

On the basis of product type, the global Duchenne muscular dystrophy (DMD) treatment market is segmented into

• Pain management drugs
• Corticosteroids

On the basis of end-users, the global Duchenne muscular dystrophy (DMD) treatment market is segmented into

• Hospitals
• Home care settings
• clinics

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/898

Regional Outlook

Growing patient population in North America and Europe is the factor contributing to the growth of global Duchenne muscular dystrophy (DMD) treatment market in these regions

Regional segmentation of Duchenne muscular dystrophy (DMD) treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Among regions, North America holds dominant position in the global Duchenne muscular dystrophy treatment market. This is owing to robust healthcare facilities in this region. Furthermore, Europe is expected to witness significant growth during the forecast period, owing to high rate of DMD cases in the region. For instance, according to Center for Disease Control and Prevention (CDC), in North England, 233 out of 1.49 million male patients were reported for DMD or other muscular dystrophy cases in 2009.

Competitive Landscape

Key players are involved in the research and development of novel drug therapy for the treatment of Duchenne muscular dystrophy (DMD)

Key players in the market are focused on research and development of novel drugs for treatment, and strategies such as collaboration and partnership are adopted by companies to hold the major share in the Duchenne muscular dystrophy (DMD) treatment market. For instance, in 2014, PTC Therapeutics International Limited obtained conditional approval and orphan drug designation for Translarna, which is a novel gene therapy for the treatment of Duchenne muscular dystrophy.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/duchenne-muscular-dystrophy-treatment-market-898

Key players operating global Duchenne muscular dystrophy (DMD) treatment market are SUMMIT Therapeutics Plc., PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics, Pfizer Incorporated, and Pharmacia & Upjohn LLC.

Table of Content

Global Duchenne Muscular Dystrophy (DMD) Treatment Market Research Report
Section 1: Global Duchenne Muscular Dystrophy (DMD) Treatment Industry Overview
Section 2: Global Economic Impact on Duchenne Muscular Dystrophy (DMD) Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Duchenne Muscular Dystrophy (DMD) Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837